Resistance to antitubercular drugs

Advances in Experimental Medicine and Biology

Volumn 456, Issue , 1998, Pages 115-144

  Basso, L A ^a   Blanchard, J S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERACTINOMYCIN; TUBERCULOSTATIC AGENT; VIOMYCIN;

ANTIBACTERIAL ACTIVITY; CROSS RESISTANCE; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 0032226549     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4897-3_7     Document Type: Review

References (188)

1. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication
2. Characteristics of patients with drug resistant and drug sensitive tuberculosis in East London between 1984 and 1992
3. Mutations in ribosomal S4 and S12 influence the higher order structure of 16S ribosomal RNA
4. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis
5. A mechanism of drug action revealed by structural studies of enoyl reductase
6. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis
7. Kinetics of inactivation of WT and C243S mutant of Mycobacterium tuberculosis enoyl reductase by activated isoniazid
8. Purification and partial characterization of a penicillin-binding protein from Mycobacterium smegmatis
9. Antibiotic resistance: A view from the pharmaceutical industry
10. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol
11. Mechanisms of antibiotic resistance in bacteria
12. Sequences of the envM gene and two mutated alleles in Escherichia coli
13. Protein envM is the NADH-dependent enoyl-ACP reductase (fabl) of Escherichia coli
14. Chemotherapy of experimental tuberculosis
15. Lipids and carbohydrates of Mycobacterium tuberculosis
16. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis
17. Nationwide survey of drug-resistant tuberculosis in the United States
18. Tuberculosis: Commentary on a reemergent killer
19. The envelope of mycobacteria
20. Classification and structure-activity relationships of fluoroquinolones
21. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity
22. Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis
23. The J. Burns Amberson lecture: Present aspects of bacterial resistance in tuberculosis
24. Crisis in infectious diseases: Time for a new paradigm?
25. DNA gyrase and topoisomerase IV on the bacterial chromosome: Quinolone-induced DNA cleavage
26. Viomycin resistance: Alterations of either ribosomal subunit affect the binding of the antibiotic to the pair subunit and the entire ribosome becomes resistant to the drug
27. Characterization of the Mycobacterium tuberculosis phagosome
28. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance
29. Drug-resistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD global surveillance project
30. Mycobacterium tuberculosis: Drug-resistance mechanisms
31. Bacterial resistance mechanisms as targets
32. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City
33. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or M. avium in cultured human macrophages are not acidic
34. Resistance to D-cycloserine in the tubercle bacilli: Mutation rate and transport of alanine in parental cells and drug-resistant mutants
35. Drug resistance to M. tuberculosis and other Mycobacteria
36. Inhibition of the synthesis of wax D peptidoglycolipid of Mycobacterium tuberculosis by D-cycloserine
37. Susceptibility of mycobacterial D-alanyl-D-alanine synthetase to D-cycloserine
38. Drug treatment of tuberculosis
39. Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope
40. Lung specific stealth liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice
41. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis
42. Oxidative stress response and its role in sensitivity to isoniazid in mycobacteria: Characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis
43. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis
44. Isolation of the gene for the β subunit of RNA polymerase from rifampicin-resistant Mycobacterium tuberculosis and identification of new mutations
45. A ribosomal gene mutation in streptomycin-resistant Mycobacterium tuberculosis isolates
46. The treatment of tuberculosis
47. Resistance to β-lactams in Mycobacterium fortuitum
48. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones
49. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: Alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot
50. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli
51. The emergence of drug-resistant tuberculosis in New York City
52. Identification, cloning, and expression of the Escherichia coli pyrazinamidase and nicotinamidase gene, pncA
53. Influence of the medium on the in vitro susceptibility of Mycobacterium tuberculosis to ethambutol
54. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii
55. The biosysnthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Identification and functional analysis of CMAS-2
56. Molecular structures of penicillin binding proteins and β-lactamases
57. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin
58. Bacteriologic basis of short course chemotherapy for tuberculosis
59. Phenotypic conversion of drug-resistant bacteria to drug sensitivity
60. Antimycobacterial drugs
61. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis
62. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations
63. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis
64. Drug-resistant tuberculosis: Inconsistent results of pyrazinamide susceptibility testing
65. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis
66. Isolation and characterization of isoniazid-resistant mutants of Mycobacterium smegmatis and M. aurum
67. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: A molecular study
68. Deoxyribonucleic acid replication time in Mycobacterium tuberculosis H37 Rv
69. Primary drug resistance: A continuing study of drug resistance in tuberculosis in a veteran population within the United States. X. September 1970 to September 1973
70. Molecular basis of rifampin resistance in Mycobacterium leprae
71. Streptomycin resistance in mycobacteria
72. The changing face of tuberculosis
73. Activity of quinolones against mycobacteria
74. Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo
75. Interplay of cell wall barrier and β-lactamase activity determines high resistance to β-lactam antibiotics in Mycobacterium chelonae
76. Mycobacterial cell wall: Structure and role in natural resistance to antibiotics
77. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis
78. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis
79. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase β subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas
80. Rapid mycobacterium species assignment and unambigous identification of mutations associated with anti-microbial resistance in Mycobacterium tuberculosis by automated DNA sequencing
81. New topoisomerase essential for chromosome segregation in E. coli
82. Purification and characterization of DNA topoisomerase IV in Escherichia coli
83. Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis
84. Perspectives on chemotherapeutic approaches to antibiotic-resistant bacteria
85. Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis
86. Effects of ethambutol on accumulation and secretion of trehalose mycolates and free mycolic acid in Mycobacterium smegmatis
87. Anti-Mycobacterium avium activity of quinolones: In vitro activities
88. Anti-Mycobacterium avium activity of quinolones: Structure-activity relationship studies
89. In vitro anti-Mycobacterium avium activities of quinolones: Predicted active structures and mechanistic considerations
90. Die aetiologie der tuberculose
91. Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria
92. Pyrazinamide susceptibility and amidase activity of tubercle bacilli
93. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis
94. Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds
95. Mechanism of D-cycloserine action: Alanine racemase from Escherichia coli W
96. Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance
97. Mycobacteria and the new quinolones
98. Dual actions of viomycin on the ribosomal functions
99. Mycolic acid structure determines the fluidity of the mycobacterial cell wall
100. Which aminoglycoside or fluroquinolone is more active against Mycobacterium tuberculosis in mice?
101. The intracellular activation of pyrazinamide and nicotinamide
102. Glycosyl transferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium
103. In vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs
104. Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: Mapping of mutations conferring resistance
105. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis
106. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro
107. Isoniazid-resistance and catalase activity of tubercle bacilli
108. Studies on isoniazid and tubercle bacilli
109. The rpoB gene of Mycobacterium tuberculosis
110. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: Comparison of Bactec method with pyrazinamidase assay
111. The action of antituberculosis drugs in short-course chemotherapy
112. Interaction of antibiotics with functional sites in 16S ribosomal RNA
113. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA
114. The inhibition of ribosomal translocation by viomycin
115. E. coli ribosomes with a C912 to U base change in the 16S rRNA are streptomycin resistant
116. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis
117. Altered permeability and β-lactam resistance in a mutant of Mycobacterium smegmatis
118. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: Restricted array of mutations associated with drug resistance
119. The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis
120. Detection of rifampin resistance in Mycobacterium tuberculosis by use of a rapid, simple, and specific RNA/RNA mismatch assay
121. The enzymatic synthesis of D-alanyl-D-alanine. III. On the inhibition of D-alanyl-D-alanine synthetase by the antibiotic D-cycloserine
122. Structure of ribosomal RNA
123. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan
124. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis
125. Reversal of drug resistance in Mycobacterium leprae by ampicillin/sulbactam
126. Use of β-lactam/β-lactamase-inhibitor combinations as antimycrobacterial agents
127. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis
128. Binding of catalase-peroxidase-activated isoniazid to wild-type and mutant Mycobacterium tuberculosis enoyl-ACP reductases
129. Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains
130. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis
131. Inhibition of mycobactin formation in Mycobacterium smegmatis by p-aminosalicylate. A new proposal for the mode of action of p-aminosalicylate
132. Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones
133. New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains
134. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis
135. 37Ra
136. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms
137. Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene
138. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis
139. Mutation in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacilli
140. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis
141. Molecular biology, virulence, and pathogenicity of Mycobacteria
142. Peroxidase-mediated oxidation of isoniazid
143. Resistance of Mycobacterium tuberculosis in mexican patients
144. Screening of natural products for antimicrobial agents
145. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis
146. Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus
147. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities
148. Molecular characterization of the Salmonella typhimurium parE gene
149. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities
150. Ethambutol resistance in Mycobacterium tuberculosis: Critical role of embB mutations
151. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms
152. Fluoroquinolone antibiotics: Properties of the class and individual agents
153. Short-course drug therapy for tuberculosis
154. In vitro and in vivo laboratory studies of the antituberculous activity of capreomycin
155. Inhibition by ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis
156. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations
157. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis
158. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis
159. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
160. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol
161. A new synthetic compound with antituberculous activity in mice: Ethambutol (dextro-2,2′-(ethylenediimino)-di-1-butanol)
162. Activities of pefloxacin and ofloxacin against mycobacteria: In vitro and mouse experiments
163. Capreomycin susceptibility of strains resistant to streptomycin and/or viomycin
164. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei
165. DNA topoisomerases
166. Peptide antibiotics of the tuberactinomycin family as inhibitors of group I intron RNA splicing
167. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis
168. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis
169. Some new antibiotics: Penicillin V, cycloserine and candicidin
170. Tuberculosis susceptibility patterns: Predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital
171. Characterization of rifampin resistance in pathogenic Mycobacteria
172. ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex
173. Catalase and peroxidase in mycobacteria
174. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria
175. The activity of the methylpiperazinyl fluoroquinolone CG 5501: A comparison with other fluoroquinolones
176. Evidence for several higher order structural elements in ribosomal RNA
177. Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on Mycobacteria
178. Susceptibility of Mycobacteria to rifampin
179. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis
180. In vitro antimycobacterial activities of pyrazinamide analogs
181. The return of the resistant microbes
182. A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acids in Mycobacterium tuberculosis
183. Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis
184. The requirement for manganese and oxygen in the isoniazid-dependent inactivation of Mycobacterium tuberculosis enoyl reductase
185. Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations
186. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
187. Beta-lactamase inhibitors and the inducibility of the beta-lactamase of Mycobacterium tuberculosis